Shannon Nobles
Psychiatric/Mental Health · Sayre, PANPI 1447702667
Payments from drug & device makers
Across 80 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$437
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$262
- Otsuka America Pharmaceutical, Inc.$163
- Alkermes, Inc.$104
- Neurocrine Biosciences, Inc.$97
- Vanda Pharmaceuticals Inc.$89
- plus $269 from 9 others
What the payments were for
- Food & beverage$1,37497%
- Education$473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $262 |
| Otsuka America Pharmaceutical, Inc. | 10 | $163 |
| Alkermes, Inc. | 6 | $104 |
| Neurocrine Biosciences, Inc. | 5 | $97 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $49 |
| Lundbeck LLC | 3 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Noven Therapeutics, LLC | 1 | $13 |
How this compares
$1,421 in reported general payments places this provider in the 70th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 13 | $1,516 |
| Risperidone | 27 | $877 |
| Perphenazine | 11 | $818 |
| Buspirone Hcl | 47 | $763 |
| Methylphenidate ErMethylphenidate Hcl | 16 | $737 |
| Quetiapine Fumarate | 32 | $715 |
| Duloxetine Hcl | 48 | $645 |
| Clonazepam | 57 | $550 |
| Hydroxyzine Hcl | 24 | $538 |
| Escitalopram Oxalate | 45 | $502 |
| Trazodone Hcl | 41 | $445 |
| Mirtazapine | 26 | $439 |
| Bupropion XlBupropion Hcl | 35 | $407 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $400 |
| Prazosin Hcl | 23 | $384 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Sayre
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.